HOME › DRUGS › RIPRETINIB
ACTIVE SUBSTANCE / INN

RIPRETINIB

Brand name(s): QINLOCK, Qinlock
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
NDA213973
Gastrointestinal Stromal Tumors
ACTIVE SUBSTANCE
Ripretinib
REGULATORS
FDA · EMA
SPONSORS / MAH
Deciphera Pharmaceuticals (Netherlands) B.V., DECIPHERA PHARMS
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
QINLOCKNDA213973DECIPHERA PHARMSPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
QinlockDeciphera Pharmaceuticals (Netherlands) B.V.Authorised18/11/2021Gastrointestinal Stromal Tumors

FULL INTELLIGENCE ON RIPRETINIB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →